Management of intracranial metastases [including meningeal carcinomatosis] is one part of long-term systemic treatment of patients with advanced non-small cell lung cancer. Therefore, management of intracranial metastases should be started when disease is diagnosed.
Through the course of management, periodically, brain MR should be monitor and correlate the image findings with clinical manifestations and levels of plasma tumor markers and to apply and integrate any beneficial modality [including surgery, radiotherapy, targeted therapy, and immunotherapy, also guided by NGS] at the right time.
In this session, I plan to present several cases for discussion.